How real-world data is enhancing our understanding of lung cancer recurrence
While the incidence of lung cancer is decreasing over time, and survival rates are on the rise year-over-year, there is still much to learn about how to best treat this disease – and prevent its recurrence after initial therapy.
How to identify and address data biases when creating an ECA
In this blog, we’ll explore the most common biases encountered in ECAs and how to mitigate their impact on research results.
Explore the patient journey with multimodal RWD
The notoriously complex healthcare system produces enormous quantities of data every moment. A typical care delivery network might generate petabytes of clinical, financial, laboratory, and pharmaceutical information on hundreds of thousands of patients each year – yet only a tiny fraction of this data is currently used to inform treatment decisions, support the development of new therapies, and foster better patient experiences and outcomes.
Oncology LLMs: Why’d you have to go and make things so complicated?
Large language models (LLMs) like Chat-GPT and Google’s Bard are rapidly changing the way we interact with datasets that are simply too big, complex, and varied for any ordinary person to comprehend.
COTA-Powered Research will be Presented at the Annual Congress of the European Hematology Association
The fruits of COTA’s expanded research and consulting services — Real-World Insights and Real-World Support — will be on display at the annual Congress of the European Hematology Association (EHA) being held in Frankfurt and online June 8 – 11.
On the Ground at ISPOR 2023
Healthcare stakeholders gathered in Boston for ISPOR 2023 – the annual meeting to advance the science and practice of health economics and outcomes research (HEOR) around the world. Read insights and takeaways from the COTA team.
COTA, Inc. Expands Oncology Real-World Data Research & Consulting Services to Accelerate Safe, Effective Drug Development
COTA’s expanded services will provide even more support to organizations conducting research, like Bristol Myers Squibb, the US Food and Drug Administration, and Miami Cancer Institute. From protocol advisory and development to analytic and algorithmic support and publications, COTA’s expert guidance is a valuable asset for those looking to make advances in oncology research.
Building a better ECA: 5 steps for submitting an ECA to regulators
In this post we look at the future of RWD in action and explore the world of external control arms (ECAs). Experts outline 5 steps to building and submitting an ECA to regulators.
Real-world data control arm provides new look into effectiveness of lymphoma therapies
Real-world data can uncover vital efficacy info for new treatments. In the development of an external control arm for lisocabtagene maraleucel in patients with R/R large B-cell lymphoma, Bristol Myers Squibb used COTA’s RWD.
What to know about FDA draft guidance on accelerated approval of oncology drugs
Are you up to date with the latest FDA guidance on accelerated approvals for oncology therapeutics? The FDA has just released draft guidance on the use of randomized controlled trials (RCTs) versus single-arm trials for the accelerated approval of oncology therapies. We’ve broken down what you need to know.
